Reliv International Inc Quick Ratio (RELV) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Reliv International Inc  (RELV)

Reliv International Inc's Quick Ratio

RELV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Reliv International Inc's Cash & cash equivalent grew by 22.3 % in the Q3 2020 sequentially, faster than Current Liabilities, this led to improvement in Reliv International Inc's Quick Ratio to 0.71, Quick Ratio remained below Reliv International Inc average.

Within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Reliv International Inc in third quarter 2020. While Quick Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 2306 to 2515.

Explain Quick Ratio?
How much Cash & cash equivalents RELV´s has?
What are RELV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RELV Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change -7.53 % 3.12 % 6.15 % -4.16 % 19.21 %
Y / Y Cash & cash equivalent Change 31.44 % 42.32 % 18.8 % -18.05 % 7.08 %
Quick Ratio MRQ 0.71 0.6 0.55 0.43 0.5
RELV's Total Ranking # 2515 # 2306 # 2163 # 3067 # 2902
Seq. Current Liabilities Change 2.15 % -10.71 % 36.56 % -25.76 % 13.91 %
Seq. Cash & cash equivalent Change 22.3 % -3.46 % 73.45 % -35.82 % 32.42 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 785
Overall Market # 2515


Quick Ratio Statistics
High Average Low
9.27 1.01 0.39
(Dec 31 2016)   (Sep 30 2017)




Financial Statements
Reliv International Inc's Current Liabilities $ 5 Millions Visit RELV's Balance sheet
Reliv International Inc's Cash & cash equivalent $ 3 Millions Visit RELV's Balance sheet
Source of RELV's Sales Visit RELV's Sales by Geography


Cumulative Reliv International Inc's Quick Ratio

RELV's Quick Ratio for the trailling 12 Months

RELV Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth -0.59 % 6.24 % -7.77 % -18.45 % -25.58 %
Y / Y Cash & cash equivalent TTM Growth 19.24 % 12.33 % -6.2 % -21.59 % -26.94 %
Quick Ratio TTM 0.58 0.53 0.49 0.47 0.48
Total Ranking TTM # 2018 # 4602 # 4621 # 2185 # 1712
Seq. Current Liabilities TTM Growth -2.06 % 0.75 % 1.64 % -0.89 % 4.68 %
Seq. Cash & cash equivalent TTM Growth 8.21 % 9.1 % 5.28 % -4.07 % 1.94 %

Quick ratio ranking by company, industry and sector >> Back to RELV Financial Strength Comparisons >> Go to Compare RELV Quick Ratio to its Competitors

On the trailing twelve months basis RELV Cash & cash equivalent grew by 31.44 % in Q3 2020 year on year, while Current Liabilities rose to $5 millions, this led to increase in in Reliv International Inc's Quick Ratio to 0.58, Quick Ratio remained below RELV average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 394 other companies have achieved higher Quick Ratio than Reliv International Inc. While Quick Ratio overall ranking has improved so far to 2018, from total ranking during the twelve months ending second quarter 2020 at 4602.

Explain Quick Ratio?
How much Cash & cash equivalents RELV´s has?
What are RELV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 395
Healthcare Sector # 689
Within the Market # 2018


trailing twelve months Quick Ratio Statistics
High Average Low
0.81 0.63 0.46
(Sep. 30, 2014)   (Jun 30 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Cartesian Therapeutics Inc   1.90 $ 146.261  Millions$ 77.004  Millions
Clearside Biomedical Inc   1.89 $ 14.839  Millions$ 7.837  Millions
Immunogen inc   1.89 $ 188.217  Millions$ 99.821  Millions
Biodelivery Sciences International Inc   1.88 $ 100.177  Millions$ 53.409  Millions
Inmed Pharmaceuticals Inc  1.87 $ 4.584  Millions$ 2.453  Millions
Verrica Pharmaceuticals Inc   1.84 $ 71.881  Millions$ 39.003  Millions
Clovis Oncology inc   1.81 $ 224.702  Millions$ 123.958  Millions
Avalo Therapeutics Inc   1.81 $ 33.523  Millions$ 18.571  Millions
Beyondspring Inc   1.78 $ 30.874  Millions$ 17.350  Millions
Aytu Biopharma Inc  1.76 $ 37.911  Millions$ 21.506  Millions
Biomarin Pharmaceutical Inc  1.76 $ 1,505.673  Millions$ 854.693  Millions
Sinovac Biotech Ltd  1.74 $ 1,185.452  Millions$ 679.610  Millions
Alexion Pharmaceuticals Inc   1.73 $ 2,296.900  Millions$ 1,331.000  Millions
Universe Pharmaceuticals Inc  1.72 $ 10.058  Millions$ 5.832  Millions
Therapeuticsmd Inc   1.68 $ 79.634  Millions$ 47.330  Millions
Myovant Sciences Ltd   1.67 $ 111.296  Millions$ 66.757  Millions
Grace Therapeutics Inc  1.65 $ 6.064  Millions$ 3.670  Millions
Biolinerx Ltd   1.58 $ 16.831  Millions$ 10.641  Millions
Camp4 Therapeutics Corporation  1.58 $ 107.145  Millions$ 68.016  Millions
Zoetis Inc   1.52 $ 3,654.000  Millions$ 2,400.000  Millions
Alkermes Plc   1.51 $ 569.382  Millions$ 378.151  Millions
Akebia Therapeutics Inc   1.48 $ 269.255  Millions$ 181.458  Millions
Celyad Oncology Sa  1.46 $ 19.302  Millions$ 13.254  Millions
Summit Therapeutics Inc   1.44 $ 27.483  Millions$ 19.048  Millions
Societal Cdmo Inc   1.44 $ 21.487  Millions$ 14.917  Millions
Endo International Plc  1.43 $ 1,842.386  Millions$ 1,290.998  Millions
Urogen Pharma Ltd   1.42 $ 25.057  Millions$ 17.618  Millions
Lexicon Pharmaceuticals Inc   1.41 $ 111.446  Millions$ 78.922  Millions
Protagenic Therapeutics Inc new  1.39 $ 0.989  Millions$ 0.712  Millions
Emergent Biosolutions Inc   1.39 $ 415.000  Millions$ 299.300  Millions

Date modified: 2026-09-26T07:11:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.